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Introduction: Newborn Screening (NBS) for Cystic Fibrosis (CF) is today an
unquestionable tool for the public health system. It allows an early diagnosis, a
timely treatment, a better quality of life, and growth improvement. It also offers
the best scenario for genetic counseling and family planning. Although, NBS for
CF is mandatory in Argentina since 1994, it was not until 2008 that the law was
regulated in Buenos Aires Province (BA). Moreover, since Jul/10, NBS is part of the
Diagnosis and Treatment for Congenital Diseases Program (PRODyTEC), Ministry
of Health (BA). Before then, NBS scope was limited mostly to private sector and
made mainly upon request.
Objective: To present NBS for CF results for the period Jul/95-Dec/11 using
IRT/IRT and sweat test as conﬁrmation.
Materials and Methods: IRT measurements were performed using DELFIA
technology (cut off value 70 ng/ml). Since the strategy did not consider searching
for mutations, genetic testing was carried out only after sweat test conﬁrmation.
Results: Along the ﬁrst 15 years, 1.168.524 newborns (NB) were screened, 85%
being BA natives and the rest from other provinces. In 2011, 200.463 NB (86.7%
from BA) were tested, reaching coverage of 60% of total NB. 166 NB were
conﬁrmed with CF, giving an incidence rate of 1:7.039. 13 of these NB corresponded
to false negative, but only 5 were true cases, the remaining presented meconium
ileus (MI) at birth.
Conclusions: Recall rate, sensitivity (excluding MI) and speciﬁcity were 0.55%,
96.8% and 99.96% respectively. Similar values are reported in the literature for
IRT/IRT.
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Objectives: Cystic ﬁbrosis (CF) is one of the most frequently diagnosed autosomal-
recessive diseases in the Caucasian population. Screening for Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) gene mutations, including poly T,
is strongly recommended in infertile couples planning a pregnancy by assisted
reproductive technology (ART). This study evaluated the performance of the new
Nanochip CF70 kit (Savyon Diagnostic, Israel), a microarray assay, and compared
it with the Innolipa kits (Innogenetics, Belgium).
Methods: From January to July 2012 we analyzed 392 blood samples with
Innolipa and Nanochip technologies that identify respectively 70 and 56 CFTR
mutations. Both tests include the most common Italian mutations and the poly-T
screening. Discordant results were analyzed with the Devyser CFTR Core Kit
(Devyser, AB, Sweden), MLPA (MRC Holland), Direct Sequencing (DS) on the
3730 DNA Analyzer (AppliedBiosystems), and Sequenom’s MassArray system
(Diatechpharmacogenetics, Italy).
Conclusion: Innolipa and NanoChip were concordant for 371/392 samples. 21/392
(0.5%) discordant results were tested with the aforementioned technologies: DS
conﬁrmed Innolipa results in 18/21 samples and Nanochip results in 1/21, while
Devyser and Sequenom did not recognize some mutations not included in their
panels. DS was essential for the identiﬁcation of two different homozygous dele-
tions; although they were not present in Innolipa panels, in 2/21 samples Innolipa
indicated a mutation with the warning no interpretation possible
In this study the Innolipa assay conﬁrmed its reliability and Nanochip showed that
it could become competitive with slight changes to the software.
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Objectives: Within the nationwide cystic ﬁbrosis (CF) neonatal screening (NBS)
scheme we assessed the uptake of post-NBS genetic counseling (GC), together
with DNA testing assessment. Within the “IRT/DNA/IRT” NBS scheme GC is
proactively offered to the parents of an ascertained newborn with 1 or 2 CFTR
mutations.
Methods: GC reports and our internal CF database were used for data collection.
Results: Since August 2009, 201 newborns with 1 or 2 mutations were identiﬁed
of which 35 suffered from CF, 5 had equivocal diagnosis of CF (EDG), including
detection of 161 carriers. Parents of 179 cases (90.0%; i.e. one or both parents)
underwent GC. Provision of GC was not documented in 5 instances (2.5%), while 15
(7.5%) families declined GC. Altogether DNA testing was performed in 156 (77%)
cases. Both parents were tested in 129 newborns (comprising 26 CF patients, 3 EDG
cases and 100 carriers), only mothers were tested in 26 newborns (3 CF patients,
1 EDG and 22 carriers), including father of a carrier. In the parents of CF carriers
DNA testing revealed a couple with the 25% risk of CF and 6 highly likely cases of
non-paternity, i.e. with no mutation identiﬁed. The “obligate” carrier status of each
parent of the 29 children with 2 mutations found within CF NBS was conﬁrmed.
Conclusions: The uptake of GC is high. However, deceased infants with 1 CFTR
mutation and no sweat test result, children with EDG and revelation of non-paternity
in parents of CF carriers demonstrate some of the difﬁcult GC issues in CF NBS.
Implementation of the IRT/PAP/DNA protocol would reduce the number of DNA
tests and thus decrease DNA testing-related CF NBS burden.
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Background: A wide variety of physiological or medical conditions have been
associated with hypertrypsinaemia in the neonatal period. A slightly higher im-
munoreactive trypsin (IRT) concentrations has been reported in babies of North
African parentage than in babies of North European origin.
Objectives: To analyze the IRT levels and the rate of Cystic Fibrosis Newborn
Screening (CF NBS) false positives (FP) in Maghribian newborns as compared
with babies of other ethnic groups in a ethnically diverse Spanish Region (Murcia).
Methods: A three-stage (IRT1/IRT2/DNA) protocol, using the sweat chloride con-
centration for discriminating between false and true positives, has been performed in
Murcia since March 2007. T-student and Chi2 tests were used to assess differences
between both populations regarding FP ratio and IRT levels.
Results: In last 6 years, 106 infants (21 North Africans, mostly from Morocco,
and 85 of other ethnic groups) with a FP result of the NBS have been referred
to our CF unit. According to current population census in Murcia, it means that
the rate of FP is 6.08 per 100,000 inhabitants among non-Maghribians and 27.8
per 100,000 inhabitants among Maghribians; OR 4.56 (IC95% 2.83; 7.35). Mean
IRT1 level was 81.8±26.6 ng/ml in the ﬁrst group and 106.7±101 ng/ml in the
second one (p 0.055); mean IRT2 level was 61.2±15.3 ng/ml in the ﬁrst group and
96.3±79 ng/ml in the second one (p 0.0003).
Conclusions: In our population, the rate of FP and IRT levels (mainly the second
tier) are much higher in newborns of Maghribian origin as compared with those of
other ethnic groups. Maybe, we should adjust IRT cut-off to ethnic origin.
